Comparing the current results to its competitors, Adma Biologics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -0.3 %, despite the revenue increase by the most of its competitors of 6.08 %, recorded in the same quarter.
Adma Biologics Inc Net Income in the 1 quarter 2026 grew year on year by 68.48%, faster than the Adma Biologics Inc 's competitors average income growth of 60.43 %
Adma Biologics Inc 's Comment on Competition and Industry Peers
The plasma products industry is characterized by intense competition from both U.S.-based and international producers. Key competitors include CSL Behring, Grifols, Takeda, Octapharma, BPL/Kedrion, and ADMA Biologics. In the United States, the primary producers of plasma-derived products are CSL Behring, Grifols, Takeda, and ADMA Biologics. Competition also arises from smaller local companies and from non-plasma products such as recombinant Factor VIII. In Europe, local companies may benefit from greater familiarity with healthcare systems, established infrastructures, existing regulatory approvals, and knowledge of regulatory processes, which can facilitate faster product marketing.
CVS Health Corporation operates as a diversified health care company that integrates pharmacy services, retail health products, and health care programs to enhance patient access to care. Their business model emphasizes the convenience of one-stop shopping by combining retail locations, pharmacy distribution, and clinical services, which includes MinuteClinic walk-in clinics for immediate care. To foster customer loyalty, CVS Health leverages personalized services, digital engagement, and initiatives like the ExtraCare rewards program, creating a holistic health experience for consumers.
Emergent Biosolutions Inc's business model focuses on developing and manufacturing specialty products for the prevention and treatment of public health threats.
Grifols SA operates a business model that focuses on plasma-derived medicine production and commercialization, including plasma collection, testing, and fractionation, as well as the development of diagnostic equipment and transfusion medicine. Their core activities involve the extraction of plasma, transforming it into life-saving therapies, and distributing them worldwide to healthcare providers.
Sources:
Adma Biologics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Adma Biologics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
